Astria Therapeutics Inc - Understand $atxs stock

$ATXS Market Cap: $655.1 Million

Research Board Inbox Deep Research Not Interested Shortlisted

Financial Snapshot

Revenue

$0.00

TTM

Gross Margin

Net Earnings

-$93.24M

TTM

Current Assets

$357.9M

Q2 2024

Current Liabilities

$16.37M

Q2 2024

Current Ratio

2186.52%

Q2 2024

Total Assets

$368.0M

Q2 2024

Total Liabilities

$20.91M

Q2 2024

Book Value

$347.1M

Q2 2024

Cash

$87.21M

Q2 2024

P/E

-7.026

Sep 18, 2024 EST

Free Cash Flow

-$61.61M

TTM

Revenues

Revenue YoY Change

Revenues

Concept	2023	2022	2021	2020	2019	2018	2017	2016	2015	2014	2013	2012
Revenue	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$500.0K	$0.00	$0.00	$0.00	$0.00	$0.00
YoY Change						-100.0%

Expenses

Cost Of Revenues

Gross Profit

Gross Profit Margin

Gross Profit

Concept	2023	2022	2021	2020	2019	2018	2017	2016	2015	2014	2013	2012
Revenue	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$500.0K	$0.00	$0.00	$0.00	$0.00	$0.00
Cost Of Revenue
Gross Profit
Gross Profit Margin

Selling, General & Admin Expense

Research & Development

Depreciation, Depletion & Amortization

SGA Expense to Gross Profit Ratio

R&D To Gross Profit Ratio

DDA To Gross Profit Ratio

Operating Expenses Total

Operating Profits/Loss

Operational Expenses

Concept	2023	2022	2021	2020	2019	2018	2017	2016	2015	2014	2013	2012
Selling, General & Admin	$25.70M	$19.24M	$14.81M	$11.85M	$8.771M	$9.329M	$8.912M	$10.11M	$8.630M	$6.000M	$4.130M	$3.270M
YoY Change	33.6%	29.93%	25.01%	35.05%	-5.98%	4.68%	-11.83%	17.13%	43.83%	45.28%	26.3%
% of Gross Profit
Research & Development	$42.13M	$34.26M	$15.55M	$25.59M	$18.32M	$17.04M	$18.68M	$25.45M	$23.03M	$15.69M	$13.99M	$12.41M
YoY Change	22.95%	120.32%	-39.23%	39.71%	7.48%	-8.78%	-26.59%	10.51%	46.78%	12.15%	12.73%
% of Gross Profit
Depreciation & Amortization					$26.00K	$119.0K	$304.0K	$395.0K	$200.0K	$250.0K	$320.0K	$330.0K
YoY Change					-78.15%	-60.86%	-23.04%	97.5%	-20.0%	-21.88%	-3.03%
% of Gross Profit
Operating Expenses	$83.03M	$53.50M	$195.0M	$37.44M	$27.09M	$26.37M	$27.59M	$35.56M	$31.66M	$21.68M	$18.12M	$15.67M
YoY Change	55.19%	-72.56%	420.84%	38.2%	2.72%	-4.43%	-22.4%	12.31%	46.03%	19.65%	15.63%
Operating Profit	-$83.03M	-$53.50M	-$195.0M	-$37.44M
YoY Change	55.19%	-72.56%	420.84%

Interest Expenses

Interest Expenses To Operating Income %

Other Expense/Income

Interest & Other Expense/Income

Concept	2023	2022	2021	2020	2019	2018	2017	2016	2015	2014	2013	2012
Interest Expense	$10.20M	$1.724M	$122.0K	$236.0K	$845.0K	$325.0K	-$302.0K	-$595.0K	-$980.0K	-$210.0K	$0.00	$0.00
YoY Change	491.71%	1313.11%	-48.31%	-72.07%	160.0%	-207.62%	-49.24%	-39.29%	366.67%
% of Operating Profit
Other Income/Expense, Net	$10.14M	$1.669M	$64.00K	$135.0K	-$50.00K	$176.0K	$32.00K	$93.00K	$10.00K	$0.00	$0.00	$0.00
YoY Change	507.49%	2507.81%	-52.59%	-370.0%	-128.41%	450.0%	-65.59%	830.0%

Income/Loss

Pretax Income

Income Tax

Net Profits/Loss

Pretax Income YoY Change

Income Tax Rate

Net Profits/Loss YoY Change

Basic EPS

Net Income To Revenue Ratio

Pretax & Net Income

Concept	2023	2022	2021	2020	2019	2018	2017	2016	2015	2014	2013	2012
Pretax Income	-$72.89M	-$51.83M	-$194.9M	-$37.30M	-$26.29M	-$25.87M	-$27.36M	-$36.06M	-$32.63M	-$21.88M	-$18.12M	-$15.67M
YoY Change	40.62%	-73.41%	422.55%	41.86%	1.64%	-5.46%	-24.12%	10.51%	49.13%	20.75%	15.63%
Income Tax							$0.00
% Of Pretax Income
Net Earnings	-$72.89M	-$51.83M	-$194.9M	-$37.30M	-$26.29M	-$25.87M	-$27.36M	-$36.06M	-$32.63M	-$21.88M	-$18.12M	-$15.67M
YoY Change	40.62%	-73.41%	422.55%	41.86%	1.64%	-5.46%	-24.12%	10.51%	49.13%	20.75%	15.63%
Net Earnings / Revenue							-5472.8%
Basic Earnings Per Share	-$2.42	-$3.55	-$24.58	-$12.20
Diluted Earnings Per Share	-$2.42	-$3.55	-$24.58	-$12.20	-$14.09M	-$30.71M	-$75.72M	-$133.3M	-$125.50	-$95.13	-$78.78	-$68.13

Assets & Liabilities

Cash & Short-Term Investments

Cash & Equivalents

Cash To Operating Expenses Ratio

Inventory

Receivables

Total Short-Term Assets

Property, Plant And Equipment

Long-Term Investments

Total Long-Term Assets

Total Assets

Net Income To Total Assets Percentage

Accounts Payable

Short-Term Debt

Long Term Debt Due

Total Short-Term Liabilities

Long-Term Debt

Other Long-Term Liabilities

Total Long-Term Liabilities

Total Liabilities

Short-Term To Long-Term Debt Ratio

Short-Term Assets To Debt Ratio

Long-Term Debt To Net Income Ratio

Assets & Liabilities

Concept	2023	2022	2021	2020	2019	2018	2017	2016	2015	2014	2013	2012
Cash & Short-Term Investments	$246.5M	$226.4M	$125.5M	$44.93M	$36.24M	$37.57M	$16.37M	$38.53M	$62.80M	$14.70M	$30.50M	$5.400M
YoY Change	8.87%	80.42%	179.34%	23.97%	-3.53%	129.52%	-57.51%	-38.65%	327.21%	-51.8%	464.81%
Cash & Equivalents	$7.709M	$1.944M	$1.853M	$23.00M	$5.432M	$5.956M	$16.37M	$23.60M	$62.80M	$13.50M	$29.00M	$4.000M
Short-Term Investments	$71.00M	$205.9M	$39.00M	$20.00M	$26.35M	$22.28M	$0.00	$14.93M	$0.00			$0.00
Other Short-Term Assets	$4.412M	$1.253M	$1.567M	$1.395M	$2.714M	$1.345M	$1.094M	$1.001M	$800.0K	$400.0K	$100.0K	$200.0K
YoY Change	252.11%	-20.04%	12.33%	-48.6%	101.78%	22.94%	9.29%	25.12%	100.0%	300.0%	-50.0%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets	$250.9M	$227.7M	$127.1M	$46.33M	$38.96M	$38.92M	$17.46M	$39.53M	$63.60M	$15.00M	$30.60M	$5.600M
YoY Change	10.21%	79.18%	174.31%	18.91%	0.11%	122.84%	-55.82%	-37.85%	324.0%	-50.98%	446.43%
Property, Plant & Equipment	$363.0K	$948.0K	$394.0K	$966.0K	$2.349M	$56.00K	$321.0K	$568.0K	$500.0K	$300.0K	$300.0K	$600.0K
YoY Change	-61.71%	140.61%	-59.21%	-58.88%	4094.64%	-82.55%	-43.49%	13.6%	66.67%	0.0%	-50.0%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets	$3.361M	$1.995M	$45.00K	$165.0K	$473.0K	$198.0K	$113.0K	$113.0K	$100.0K	$700.0K	$100.0K	$100.0K
YoY Change	68.47%	4333.33%	-72.73%	-65.12%	138.89%	75.22%	0.0%	13.0%	-85.71%	600.0%	0.0%
Total Long-Term Assets	$3.724M	$2.943M	$439.0K	$1.131M	$2.822M	$254.0K	$434.0K	$681.0K	$600.0K	$1.000M	$400.0K	$700.0K
YoY Change	26.54%	570.39%	-61.18%	-59.92%	1011.02%	-41.47%	-36.27%	13.5%	-40.0%	150.0%	-42.86%
Total Assets	$254.7M	$230.6M	$127.5M	$47.46M	$41.78M	$39.17M	$17.90M	$40.21M	$64.20M	$16.00M	$31.00M	$6.300M
YoY Change
Accounts Payable	$1.513M	$788.0K	$1.557M	$1.544M	$1.197M	$1.408M	$773.0K	$1.405M	$1.300M	$1.100M	$700.0K	$800.0K
YoY Change	92.01%	-49.39%	0.84%	28.99%	-14.99%	82.15%	-44.98%	8.08%	18.18%	57.14%	-12.5%
Accrued Expenses	$10.04M	$8.272M	$3.646M	$4.846M	$3.835M	$2.763M	$2.432M	$3.677M	$3.300M	$2.800M	$2.300M	$1.100M
YoY Change	21.34%	126.88%	-24.76%	26.36%	38.8%	13.61%	-33.86%	11.42%	17.86%	21.74%	109.09%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due						$0.00	$2.479M	$3.243M	$3.200M	$300.0K
YoY Change						-100.0%	-23.56%	1.34%	966.67%
Total Short-Term Liabilities	$11.55M	$9.060M	$5.203M	$6.390M	$5.032M	$4.171M	$6.016M	$8.325M	$7.800M	$4.200M	$2.900M	$1.900M
YoY Change	27.48%	74.13%	-18.58%	26.99%	20.64%	-30.67%	-27.74%	6.73%	85.71%	44.83%	52.63%
Long-Term Debt	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$2.479M	$5.700M	$4.400M	$0.00	$0.00
YoY Change							-100.0%	-56.51%	29.55%
Other Long-Term Liabilities	$0.00	$357.0K	$0.00	$397.0K	$1.028M	$56.00K	$89.00K	$319.0K	$200.0K	$200.0K	$100.0K	$100.0K
YoY Change	-100.0%		-100.0%	-61.38%	1735.71%	-37.08%	-72.1%	59.5%	0.0%	100.0%	0.0%
Total Long-Term Liabilities	$0.00	$357.0K	$0.00	$397.0K	$1.028M	$56.00K	$89.00K	$2.798M	$5.900M	$4.600M	$100.0K	$100.0K
YoY Change	-100.0%		-100.0%	-61.38%	1735.71%	-37.08%	-96.82%	-52.58%	28.26%	4500.0%	0.0%
Total Liabilities	$11.55M	$9.417M	$5.203M	$6.787M	$6.060M	$4.227M	$6.105M	$11.12M	$13.70M	$8.900M	$3.000M	$2.000M
YoY Change	22.65%	80.99%	-23.34%	12.0%	43.36%	-30.76%	-45.11%	-18.81%	53.93%	196.67%	50.0%

Ownership

Basic Shares Outstanding

Diluted Shares Outstanding

Preferred Stock

Treasury Stock Shares

Stock Issuance & Repurchase

Ownership Data

Concept	2023	2022	2021	2020
Basic Shares Outstanding	30.12M	14.62M	8.925M	3.059M
Diluted Shares Outstanding	30.12M	14.62M	8.925M	3.059M
Preferred Stock
Treasury Stock Shares

Return On Shareholders' Equity

Book Value

Free Cash Flow

Free Cash Flow YoY

Dividends

Stock Price

Market Cap: $655.1 Million

About Astria Therapeutics Inc

Astria Therapeutics, Inc. engages in the discovery, development, and commercialization of novel therapeutics. The company is headquartered in Boston, Massachusetts and currently employs 59 full-time employees. The company went IPO on 2015-06-25. The firm's lead program, STAR-0215, is a monoclonal antibody inhibitor of plasma kallikrein in clinical development for the treatment of hereditary angioedema (HAE), a rare, debilitating and potentially life-threatening disease. Its second program, STAR-0310, is a monoclonal antibody OX40 antagonist in preclinical development for the treatment of atopic dermatitis (AD). The firm owns two patent families directed to STAR-0215. The first patent family is directed to the composition of matter of its product candidate STAR-0215 and its use in treating various plasma kallikrein associated disorders including HAE. In the second patent family, the Company owns one International (PCT) patent application directed to methods of treating various plasma-kallikrein associated disorders, including HAE, with specific dosing regimens of the STAR-0215 antibody.

Industry: Pharmaceutical Preparations Peers: AVITA Medical Inc DermTech Inc INmune Bio Inc Syros Pharmaceuticals Inc Olema Pharmaceuticals Inc PepGen Inc Oric Pharmaceuticals Inc Praxis Precision Medicines Inc Tenaya Therapeutics Inc